Acute dystonia during pegylated interferon alpha therapy in a case with chronic hepatitis B infection.

Abstract

Interferon (IFN) is the most widely prescribed drug of choice for chronic hepatitis B infection, which is a common health problem in our country. Therapy with IFN-alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and depressive disorders. In this case report, we present clinical and laboratory findings of a case with chronic hepatitis B that developed acute dystonia soon after the first dose of pegylated interferon alpha. As far as we know, this is the first report in English literature indicating such an adverse effect of pegylated interferon alpha.

• Authors: Nuray Atasoy, Yucel Ustundag, Numan Konuk, Levent Atik
• Journal: Clinical neuropharmacology (Clin Neuropharmacol) 2004 May-Jun Vol. 27 Issue 3 Pg. 105-7 ISSN: 0362-5664 [Print] United States
• PMID: 15190230 (Publication Type: Case Reports, Journal Article)

Chemical References

• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins
• Polyethylene Glycols
• peginterferon alfa-2a

Topics

• Adult
• Dystonia (chemically induced)
• Hepatitis B, Chronic (complications, drug therapy)
• Humans
• Interferon alpha-2
• Interferon-alpha (adverse effects, therapeutic use)
• Male
• Polyethylene Glycols (adverse effects, therapeutic use)
• Recombinant Proteins